Pushing the limits of targeted therapy in chronic myeloid leukaemia.
Article Details
- CitationCopy to clipboard
O'Hare T, Zabriskie MS, Eiring AM, Deininger MW
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.
- PubMed ID
- 22825216 [ View in PubMed]
- Abstract
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.
DrugBank Data that Cites this Article
- Drugs